Second clinical failure of Transgene in 2019French Transgene SA said it has terminated its lead programme TG4010 in combination with chemotherapy and checkpoint inhibition. more ➔
Microbiota contribute to skin damage in cancer therapy New research demonstrates that disruption of EGF receptor signalling allows commensal bacteria to invade hairs and cause skin lesions. more ➔
BIOncoTech Therapeutics and MSD combine cancer drugsMadrid-based RNA specialist Bioncotech Therapeutics has entered into a Phase II clinical trial collaboration with a MSD subsidiary. more ➔
Urokinase clears blot clots in stroke patientsSwiss surgeons have significantly improved mechanical removal of blood clots in stroke patients by intra-arterial administration of the thromolytic urokinase. more ➔
Sanofi buys Synthorx Inc for US$2.35bnSanofi will acquire Synthorx Inc to expand its immuno-oncology pipeline with THOR-707, an optimised IL-2 candidate. more ➔
Meatable NV raises US$10m in seed fundingMeatable NV, a specialist for cultivated meat, has raised an additional US$10m in seed funding, bringing the company’s total funding to US$13m. more ➔
Big Pharma is cost driver of GAVI Médecins Sans Frontières (MSF) called on the GAVI Vaccine Alliance not to pay huge subsidies to Big Pharma companies for pneumococcal vaccine more ➔
ImCheck Therapeutics SAS raises €48mT cell agonist specialist ImCheck Therapeutics will use €48m (US$53m) from a Series B financing to push clincial pipeline of antibodies activating gamma-delta T-cells. more ➔
Pierre Fabre amends license agreement with Puma BiotechnologyPierre Fabre SA and Puma Biotechnology, Inc. have broadened the geographic coverage of their license agreement on commercialisation of Nerlynx® (neratinib). more ➔
European circular bioeconomy fund near closingThe European Commission and the European Investment Bank (EIB) have selected ECBF Management GmbH as investment advisor for the €250m EU circular bioeconomy fund. more ➔
